The medical images exchange platform has now raised about $85m in total, after raising money in a round led by Cambia Health Solutions.

The healthcare management software provider, backed by UPMC and The Advisory Board, will raise the money in an upsized initial public offering.

McKesson Ventures, Cambria Health Solutions and Catholic Health Initiatives all contributed to a $13.3m series B round for the telemedicine provider.

The Blue Cross and Blue Shield Association-backed healthcare provider raised the cash in a series C round led by venture capital and private equity fund Oak HC/FT.

Karolinska Institute has signed a collaboration agreement with Johnson & Johnson Innovation and a research agreement with its Janssen Pharmaceuticals subsidiary.

The meeting of minds between IT and healthcare is a strategic move that will help accelerate big data convergence in the wider healthcare and life sciences segments. New Entrant of the Year recipient DRX Capital has capitalised on this exciting investment segment with a fellow corporate venturing unit, potentially urging others to co-fund digital health investment opportunities.

Merck Global Health Innovation Fund, the corporate venturing unit owned by pharmaceutical firm Merck, has quickly become one of the biggest corporate venturing players in the digital health segment and is dedicating a sizeable amount of its $500m fund to larger deals with private equity and other strategic partners. Given the significant impact it has made over a short period of time, there was a significant number of votes from our advisory board to make it unit of the year.

Victoria University and Malaghan Institute of Medical Research spin-out Avalia to commercialise immunotherapy treatment.

Healthcare IT technology provider ClearData has closed an oversubscribed series C round featuring existing investors Merck and Norwest Venture Partners.

Fidelity and corporate-backed Flagship Ventures provided the funding for the biotechnology company, which has now secured more than $60m altogether.